4.7 Article

Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 1, Pages 88-127

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00875

Keywords

-

Funding

  1. National Institutes of Health [R21 MH093844, R01 DA038446, K05 DA020087, P30 DA28821, T32 DA07287, F31 DA045511]
  2. R. A. Welch Foundation Chemistry and Biology Collaborative Grant from the Gulf Coast Consortia (GCC)
  3. Center for Addiction Research (CAR) at UTMB
  4. John Sealy Memorial Endowment Fund

Ask authors/readers for more resources

G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases. GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clinical trials. Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development. This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chemistry approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available